Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

HomeARTIFICIAL INTELLIGENCEVUNO Med®-DeepECG™ Designated as Breakthrough Device

VUNO Med®-DeepECG™ Designated as Breakthrough Device

Biotechnology News Magazine

South Korean artificial intelligence (AI) developer, VUNO inc. announced that the Korean Ministry of Food and Drug Safety (KFDA) has designated the company’s artificial intelligence-based electrocardiogram (ECG) analysis software VUNO Med®-DeepECG™ as the ministry’s 16th Breakthrough Device. Using deep learning, the software analyzes ECG data to zero in on heart failure, myocardial infarction and arrhythmia.

News VUNO Med®-DeepECG™ Designated as Breakthrough Device
VUNO Med®-DeepECG™

Although healthcare authorities such as the U.S. Preventive Services Task Force have pointed out the limitations of ECG tests on identifying cardiovascular diseases, the VUNO Med®-DeepECG™ can pinpoint even minute differences in ECG data that escape visual analysis by learning the ECG data of patients suffering from heart failure, myocardial infarction and other major heart-related disorders. Through this learning process, the device provides additional information on heart failure undetected in previous ECGs to identify a myocardial infarction even if no major deflections in the ECG wave patterns can be seen.

VUNO Med®-DeepECG™, once implemented in clinical practice, could help reduce mortality rates from major heart diseases and improve patient quality of life through early detection of symptomless patients through ECG testing and timely treatment.

VUNO Chairman Lee Yeha said, “VUNO will continue to deliver the value of AI to even more beneficiaries through a wide range of biosignal initiatives, including the use of ECG data with its significant potential for providing clues to serious heart-related diseases.”

VUNO is the only Korean company to be triple-designated for Breakthrough Devices, with the VUNO Med®-Fundus AI™ selected as Korea’s first Breakthrough Device and the VUNO Med®-DeepCARS™ receiving the sixth designation.

American Orthopedic Partners Adds Ted Schlegel, MD As Sr VP, Clinical Excellence

Dr. Schlegel's clinical work and research on regenerative treatments of the knee and shoulder led to the development of several innovative technologies; including the creation of an FDA-approved surgical technology (Opus Medical) that simplifies arthroscopic rotator cuff repairs.

LG and Lenovo Announce Collaboration, Driving Innovation in Radiology and Imaging

On the heels of RSNA 2021, the annual meeting of the Radiological Society of North America, the Lenovo-LG bundle will provide diagnostic and clinical solutions in key imaging areas through the combination of Lenovo ThinkStation workstations and LG Medical Monitors.

Saranas® Announces Initial Enrollment of SAFE-MCS Clinical Trial

The first patient was enrolled at Atlantic Health System’s Morristown Medical Center in Morristown, NJ, by Dr. Philippe Généreux, Co-Director of the Structural Heart Program, and Dr. Dimitrios Karmpaliotis, Medical Director of the Cardiovascular Rescue and Recovery Program and the Advanced Coronary Therapeutics and Chronic Total Occlusions Program, at Morristown Medical Center.

Colgate Family Donates $1 Million Toward Purchase of Glen Cove Hospital’s First MRI

“We are so grateful for this gift from the Colgates, which will elevate the care and comfort of all our patients,” said Kerri Scanlon, RN, FAAN, executive director of Glen Cove Hospital.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

By using this website you agree to accept Medical Device News Magazine Privacy Policy